SOUTH SAN FRANCISCO - Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotech firm focused on heart disease treatments, has reported promising preclinical findings for its small molecule histone deacetylase 6 (HDAC6) inhibitors in treating heart failure with preserved ejection fraction (HFpEF).
The research, published in the journal Nature Communications on February 26, 2024, indicates that HDAC6 inhibition could address numerous biological characteristics of HFpEF.
The study utilized a murine model to replicate the disease state and demonstrated that the HDAC6 inhibitor, TYA-018, produced direct cardiac effects, such as improved diastolic relaxation, and systemic benefits, including metabolic and inflammatory factor normalization. Notably, when combined with the FDA-approved SGLT2 inhibitor empagliflozin, the treatment showed additional benefits over either therapy alone.
HFpEF, which affects over three million Americans, is characterized by the heart muscle's inability to relax normally, leading to diastolic dysfunction. Despite its prevalence, effective treatment options have been limited. Tenaya's TN-301, a specific HDAC6 inhibitor, has completed a Phase 1 trial, showing favorable safety and pharmacokinetics that support once-daily dosing.
Tim Hoey, Ph.D., Chief Scientific Officer of Tenaya, emphasized the potential of HDAC6 inhibitors as a therapeutic strategy for HFpEF, citing the extensive preclinical data and positive Phase 1 study results.
The company's approach, leveraging its target discovery and validation capabilities, has led to the development of TN-301 and other therapies aimed at addressing genetic cardiovascular disorders and common heart conditions. Tenaya is advancing its pipeline with the goal of providing curative therapies for heart disease.
This article is based on a press release statement from Tenaya Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.